Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer
Summary
The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H&E) and IHC staining.
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Conditions
Breast Neoplasms
Intervention
OSNA Breast Cancer System
Location
John Wayne Cancer Institute
Santa Monica
California
United States
90404
Status
Completed
Source
Sysmex America, Inc.
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT01136369
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-08-27T03:13:14-0400
Clinical Trials
SLNM in Endometrial Cancer Combined With OSNA
The study compares the one-step nucleic acid amplification method (OSNA) with the histological ultrastaging examination in the assessing of sentinel lymph nodes in patients with endometria...
Study Evaluating SKI-606 in Subjects With Breast Cancer
The purpose of this study is to determine if SKI-606 is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer ...
Integral Strategy to Supportive Care in Breast Cancer Patients
The purpose of this study is to determine if it is better an integral strategy, with a m-health system, when used in addition to a supervised treatment, versus the use of the m-health syst...
Engineering Gut Microbiome to Target Breast Cancer
The purpose of this study is to find out if using probiotics will help the body's immune system react to breast cancer. New studies showed that diverse species of bacteria inside the bowel...
Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer
This study is to evaluate the efficacy and toxicity of accelerated partial breast irradiation (ABPI) with intensity modulated radiation therapy (IMRT) in low-risk breast cancer treat with ...
PubMed Articles
A new look at molecular biology of breast cancer.
In the past 25 years, incidence rates of breast cancer have risen about 30% in westernized countries. Mutations in BRCA1 and BRCA2 are the most prominent cause of breast cancer. However, these cancer...
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted the...
Phthalates, known endocrine disruptors, may play a role in breast carcinogenesis. Few studies have examined phthalates in relation to breast cancer (BC), and, to our knowledge, none have considered su...
Gene expression profiling of breast cancer has demonstrated the importance of stromal response in determining the prognosis of invasive breast cancer. The host response to breast cancer is of increasi...
Localized morphea after breast implant for breast cancer: A case report.
Early breast cancer follow-up guidelines for patients who underwent surgery suggest a regular and accurate clinical examination of the breast area, for an early identification of cutaneous or subcutan...
Medical and Biotech [MESH] Definitions
Inflammatory Breast Neoplasms
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
Breast Cancer Lymphedema
Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).
Breast Neoplasms
Tumors or cancer of the human BREAST.
Unilateral Breast Neoplasms
Tumors or cancer found specifically in one human BREAST, but not in both.
Mucin-1
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
